skin disease: Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.
Other infiltrative disorders of skin and subcutaneous tissue
DOID EFO Endpoint Browser PheWeb
L12_OTHERINFILTRATIVESKIN
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
170 |
4. Check minimum number of eventsNone |
170 |
5. Include endpointsNone |
170 |
6. Filter based on genotype QC (FinnGen only) |
170 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L98
- Name in latin
- Aliae morbositates infiltrativae cutis et textus subcutanei
Similar endpoints
↥List of similar endpoints to
Other infiltrative disorders of skin and subcutaneous tissue
based on the number of shared cases.
Similar with more cases:
- Other disorders of skin and subcutaneous tissue, not elsewhere classified
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1124 | 634 | 485 |
| Only index persons | 1034 | 597 | 437 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 55.18 | 56.99 | 52.63 |
| Only index persons | 55.43 | 57.00 | 53.29 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 170 | 104 | 66 |
| Unadjusted period prevalence (%) | 0.03 | 0.04 | 0.03 |
| Median age at first event (years) | 56.48 | 55.95 | 57.32 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 154
- Matched controls
- 1542
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L98.6
ICD-10 Finland
Other infiltrative disorders of skin and subcutaneous tissue
+∞
84.3
73
*
L98.69
ICD-10 Finland
Other infiltrative disease of the skin and subcutaneous tissue
+∞
49.7
45
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
22.8
41.2
62
44
L98.60
ICD-10 Finland
Pseudolymphoma of the skin
+∞
24.6
23
*
L98.64
ICD-10 Finland
Benign lymphocyte infiltration into the skin [Jessner-Kanof]
+∞
15.9
15
*
QAA05
NOMESCO Finland
Incision for biopsy of skin of head or neck
33.6
14.2
18
6
L98.63
ICD-10 Finland
Lymphocytoma of the skin
+∞
13.7
13
*
L93.0
ICD-10 Finland
Discoid lupus erythematosus
+∞
12.7
12
*
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
11.5
12.5
23
23
D07AC01
ATC
betamethasone; topical
3.3
11.1
78
362
L30.9
ICD-10 Finland
Dermatitis, unspecified
4.0
11.1
51
170
L98.9
ICD-10 Finland
Disorder of skin and subcutaneous tissue, unspecified
64.5
10.8
12
*
D07AD01
ATC
clobetasol; topical
4.5
10.3
39
108
D07AB08
ATC
desonide; topical
4.8
8.8
30
74
D07AC13
ATC
mometasone; topical
3.0
8.1
60
273
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
47.4
7.8
9
*
L93.2
ICD-10 Finland
Other local lupus erythematosus
+∞
7.3
7
*
P01BA02
ATC
hydroxychloroquine; oral
4.6
7.3
25
62
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
5.7
6.9
19
37
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
4.1
6.6
25
69
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
7.2
6.2
14
21
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
15
36
4.47
5.96
1.9
2.2
—
—
—
0
0
112
805
2.15
5.22
11.2
10.0
3.7
4.0
e9/l
1.04
101
709
42
212
2.30
4.81
2.1
1.8
—
—
—
0
0
31
145
2.39
4.19
1.8
1.7
—
—
—
0
0
31
149
2.32
3.94
2.0
1.8
—
—
—
0
0
92
662
1.85
3.78
8.4
6.5
1.2
1.2
mmol/l
0.20
82
563
128
1037
1.95
3.47
5.7
4.1
10.7
12.4
mm/h
1.07
122
949
45
267
1.93
3.30
4.6
3.7
275.4
157.2
ng/l
0.35
34
206
6
7
8.83
3.29
1.5
2.1
—
—
—
0
0
18
75
2.57
3.09
1.4
1.8
—
—
—
0
0
20
88
2.44
3.07
1.5
1.3
—
—
—
0
0
36
204
1.97
3.00
2.6
1.9
29.3
29.7
s
0.17
36
199
55
361
1.77
2.90
3.2
2.8
6865.7
10638.1
umol/l
0.21
49
302
46
301
1.72
2.41
2.4
1.8
1.4
1.2
mg/l
0.15
40
235
9
30
3.11
2.18
1.0
1.3
—
—
—
0
0
55
389
1.61
2.12
3.8
2.9
0.1
0.4
e6/l
2.83
40
289
5
10
5.11
2.08
1.4
1.1
—
—
—
0
0
10
38
2.73
2.05
1.0
1.1
—
—
—
0
0
9
32
2.91
2.03
1.4
1.7
—
—
—
0
0
11
45
2.54
1.97
2.6
2.1
—
—
—
0
0
9
33
2.82
1.96
1.4
1.3
—
—
—
0
0
5
11
4.65
1.95
1.2
1.5
—
—
—
0
0
5
11
4.65
1.95
1.4
1.2
—
—
—
0
0
5
11
4.65
1.95
1.8
2.5
—
—
—
0
0
5
11
4.65
1.95
1.8
2.5
—
—
—
0
0
5
11
4.65
1.95
1.8
2.5
—
—
—
0
0
6
16
3.85
1.95
1.8
1.5
—
—
—
0
0
13
59
2.30
1.89
2.3
2.3
—
—
—
0
0
20
109
1.95
1.87
4.8
3.1
61.4
63.2
ml/min/173m2
—
8
50
65
491
1.52
1.85
3.9
2.9
—
—
—
0
0
6
19
3.23
1.67
1.7
1.3
—
—
—
0
0
21
123
1.81
1.60
12.5
6.2
1.2
1.3
mmol/l
0.19
21
117
29
187
1.66
1.59
2.1
2.2
24.1
22.2
%
0.31
23
160
35
239
1.58
1.54
2.3
2.6
0.5
1.0
e6/l
1.23
19
135
5
15
3.40
1.53
1.0
1.4
—
—
—
0
0
77
621
1.44
1.52
7.2
5.8
1.2
1.2
mmol/l
0.13
71
563
6
21
2.92
1.52
1.5
1.4
—
—
—
0
0
84
689
1.43
1.51
5.4
4.9
0.0
0.0
estimate
0.00
12
131
10
45
2.30
1.49
1.0
1.2
—
—
—
0
0
10
46
2.25
1.43
2.7
2.7
0.0
0.1
g/l
—
10
46
83
686
1.41
1.40
4.1
3.6
0.0
0.0
estimate
0.00
12
128
9
41
2.26
1.39
1.8
1.4
—
—
—
0
0
41
297
1.50
1.39
1.3
1.2
1.1
0.9
u/ml
0.15
12
86
6
23
2.67
1.38
2.0
1.6
—
—
—
0
0
5
17
3.00
1.37
1.2
1.2
—
—
—
0
0
6
24
2.55
1.31
1.3
1.2
—
—
—
0
0
6
25
2.45
1.25
1.8
1.8
—
—
—
0
0
99
854
1.38
1.25
3.1
3.1
—
—
—
0
0
34
243
1.50
1.22
1.2
1.3
45.3
41.0
iu/ml
0.06
13
77
5
19
2.68
1.22
1.4
1.2
—
—
—
0
0
83
698
1.37
1.22
4.2
3.7
0.0
0.0
estimate
0.00
11
130
6
26
2.35
1.19
1.3
1.2
3.8
3.5
mmol/l
—
6
20
119
1064
1.39
1.17
4.8
4.0
14.7
14.8
pmol/l
0.18
113
964
17
104
1.71
1.14
2.4
2.4
4.1
7.1
ug/l
1.24
12
91
131
1193
1.43
1.14
22.4
17.0
13.6
13.7
%
0.33
131
1175
7
30
2.39
1.13
1.6
1.7
—
—
—
0
0
70
578
1.36
1.13
3.3
2.6
152.2
115.3
ug/l
0.64
65
530
25
170
1.55
1.13
8.5
20.7
1.1
1.3
inr
—
8
24
5
21
2.42
1.10
1.6
1.6
—
—
—
0
0
9
45
2.05
1.07
2.4
2.7
0.0
0.0
g/l
—
9
45
9
45
2.05
1.07
2.4
2.7
0.0
0.0
g/l
—
9
45
13
75
1.79
1.06
1.0
1.3
—
—
—
0
0
31
225
1.46
1.04
2.5
2.7
0.6
2.9
e6/l
2.51
15
123
64
529
1.34
1.01
4.3
3.7
—
—
—
0
0
5
23
2.21
0.98
1.6
1.6
—
—
—
0
0
9
51
1.81
0.96
2.4
2.0
—
—
—
0
0
6
28
2.18
0.92
1.5
1.3
—
—
—
0
0
68
574
1.31
0.91
2.5
2.2
80.5
75.6
nmol/l
0.84
61
497
12
71
1.74
0.91
20.9
6.3
26.0
25.0
mmol/l
0.49
12
71
32
241
1.40
0.89
1.4
1.4
—
—
—
0
0
148
1399
1.45
0.84
20.2
13.5
22.4
21.7
mg/l
0.12
125
1097
92
817
1.27
0.81
7.0
4.5
6.3
6.7
mmol/l
1.54
92
754
5
24
2.12
0.75
1.6
1.6
—
—
—
0
0
7
41
1.74
0.71
3.0
5.5
22.7
186.5
mg/l
—
7
35
7
41
1.74
0.71
2.9
5.5
47.1
26.6
mg/l
—
7
35
50
419
1.27
0.69
4.8
3.7
16.6
13.0
mg/mmol
0.12
35
250
75
660
1.24
0.69
8.3
4.1
—
—
—
0
0
5
28
1.81
0.66
3.4
1.3
—
—
—
0
0
8
49
1.66
0.63
2.5
1.8
—
—
—
0
0
136
1286
1.29
0.62
5.5
4.8
2.1
1.9
mu/l
1.11
128
1172
5
30
1.69
0.62
2.4
1.3
—
—
—
0
0
51
435
1.25
0.61
2.6
2.3
61.8
58.5
u/l
0.25
45
402
18
136
1.36
0.51
3.5
3.2
—
—
—
0
0
26
209
1.29
0.50
1.5
1.3
—
—
—
0
0
7
45
1.58
0.49
1.0
1.2
—
—
—
0
0
7
45
1.58
0.49
1.0
1.2
—
—
—
0
0
11
76
1.48
0.49
3.4
2.8
4.3
4.5
pmol/l
0.44
11
65
29
238
1.26
0.48
1.2
1.3
22.9
11.3
u/ml
0.34
16
84
19
241
0.76
0.47
3.5
2.9
0.6
0.7
ug/l
0.46
14
145
0
15
0.00
0.41
0.0
1.1
—
2.5
—
0
7
0
16
0.00
0.41
0.0
3.9
—
28.4
—
0
5
0
17
0.00
0.41
0.0
1.1
—
4.2
—
0
17
5
36
1.40
0.38
1.0
2.3
—
—
—
0
0
124
1290
0.86
0.35
22.6
15.0
39.5
40.0
%
0.30
98
959
134
1383
0.85
0.32
5.0
4.5
5.8
6.0
mmol/l
1.82
126
1265
10
75
1.35
0.31
1.1
1.1
—
—
—
0
0
139
1347
1.18
0.30
19.1
12.6
80.6
80.3
ml/min/173m2
0.04
122
1088
57
523
1.14
0.29
4.1
3.8
22.9
38.8
ng/l
1.21
39
371
8
65
1.24
0.27
2.0
1.5
—
—
—
0
0
9
76
1.19
0.25
2.1
1.3
—
—
—
0
0
5
37
1.36
0.23
1.0
1.4
—
—
—
0
0
37
335
1.13
0.23
1.9
1.5
24.8
22.0
nmol/l
0.61
32
280
10
79
1.28
0.23
23.2
8.5
25.5
24.7
mmol/l
—
10
74
5
40
1.26
0.22
2.0
1.6
26.8
39.2
nmol/l
—
5
40
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
137
1400
0.89
0.19
4.7
4.3
1.4
1.5
mmol/l
1.07
131
1282
32
351
0.89
0.19
3.1
2.1
—
—
—
0
0
9
80
1.13
0.15
2.1
2.1
—
—
—
0
0
141
1433
0.91
0.14
5.5
4.9
2.7
2.8
mmol/l
0.38
133
1312
18
161
1.13
0.13
3.7
4.6
3.3
12.6
ug/l
2.03
12
132
58
555
1.07
0.12
2.7
1.9
93.2
98.0
pmol/l
0.46
29
253
5
48
1.04
0.09
1.4
1.3
—
—
—
0
0
6
56
1.07
0.09
3.7
2.0
—
—
—
0
0
139
1407
0.93
0.08
4.9
4.4
4.6
4.7
mmol/l
0.37
134
1297
7
64
1.10
0.08
2.1
1.9
—
—
—
0
0
133
1347
0.94
0.08
4.4
3.9
1.3
1.3
mmol/l
0.27
123
1221
15
137
1.10
0.08
1.9
2.2
—
—
—
0
0
15
160
0.93
0.04
8.9
7.5
—
—
—
0
0
32
328
0.97
0.02
4.2
4.2
22.8
21.9
%
0.09
11
146
26
253
1.03
0.01
1.5
1.7
1096.4
1175.9
nmol/l
0.19
19
189
11
116
0.94
0.01
2.2
1.6
—
—
—
0
0
11
114
0.96
0.00
2.1
2.1
—
—
—
0
0
36
362
0.99
0.00
5.8
3.9
0.0
0.0
estimate
0.00
12
127
41
412
0.99
0.00
3.8
3.2
2291.5
1108.0
ng/l
0.73
36
359
0
6
0.00
0.00
0.0
2.0
—
13.5
—
0
6
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
8.2
—
241.6
—
0
5
0
8
0.00
0.00
0.0
4.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
4.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_OTHERINFILTRATIVESKIN and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_OTHERINFILTRATIVESKIN | 1.16 [0.89, 1.5] | 0.264 |
| Birth year | 0.994 [0.99, 1.0] | 0.159 |
During the follow-up period (1.1.1998 — 31.12.2019), 82 out of 583 females with L12_OTHERINFILTRATIVESKIN died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_OTHERINFILTRATIVESKIN | 1.305 [0.99, 1.71] | 0.055 |
| Birth year | 0.984 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 86 out of 442 males with L12_OTHERINFILTRATIVESKIN died.
Mortality risk
Mortality risk for people of age
years, who have L12_OTHERINFILTRATIVESKIN.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.082% | 0.224% |
| 5 | 0.767% | 1.307% |
| 10 | 1.624% | 3.239% |
| 15 | 3.128% | 6.275% |
| 20 | 5.646% | 10.793% |
Relationships between endpoints
↥Index endpoint: L12_OTHERINFILTRATIVESKIN – Other infiltrative disorders of skin and subcutaneous tissue
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data